UNIVERSITY OF NOTRE DAME Using a new technique that can identify genetic profiles of individual cells, University of Notre Dame researchers modeled a breast cancer tumor’s potential resistance to a drug, and then identified a drug combination that reversed that resistance. Siyuan Zhang, the Dee Associate Professor of Biological Sciences at Notre Dame, and his...
Post
Green tea could hold the key to reducing antibiotic resistance
by University of Surrey Scientists at the University of Surrey have discovered that a natural antioxidant commonly found in green tea can help eliminate antibiotic resistant bacteria. The study, published in the Journal of Medical Microbiology, found that epigallocatechin (EGCG) can restore the activity of aztreonam, an antibiotic commonly used to treat infections caused by...
Post
Temple scientists solve mystery underlying heart toxicity caused by diabetes drugs
TEMPLE UNIVERSITY HEALTH SYSTEM (Philadelphia, PA) – Like catching two fish with one worm, treating two problems with a single drug is efficient, but exceedingly difficult. In particular, for new diabetes medications, in which one drug aims to tackle two major complications of diabetes – the excess of both lipids and glucose in the blood – the therapeutic benefits,...
Post
Blood-brain barrier damage occurs even with mild head trauma — Ben-Gurion U study
AMERICAN ASSOCIATES, BEN-GURION UNIVERSITY OF THE NEGEV BEER-SHEVA, ISRAEL…September 25, 2019 – In a new study of adolescent and adult athletes, researchers at Ben-Gurion University of the Negev, Stanford University and Trinity College in Dublin have found evidence of damage to the brain’s protective barrier, without a reported concussion. For the first time, the researchers were able to detect damage to the blood-brain barrier (BBB), which protects the brain from...
Post
Teens sleep 43 more minutes per night after combo of two treatments, Stanford study finds
STANFORD MEDICINE Teenagers got 43 more minutes of sleep a night after a four-week intervention that reset their body clocks and helped them go to bed earlier, a study from the Stanford University School of Medicine has shown. The treatment had two components: brief, early morning flashes of bright, broad-spectrum white light to reset the teens’ circadian clocks, and cognitive behavioral therapy that motivated them to try earlier bedtimes. The findings...
Post
First CAR T cell therapy targeting B cell-activating factor receptor eradicates blood cancers
City of Hope’s research on the new CAR T, published in Science Translational Medicine, offers hope for patients who have relapsed after commercially available CD19 immunotherapy treatments CITY OF HOPE DUARTE, Calif. — The first CAR T cell therapy targeting the B cell-activating factor receptor on cancerous cells eradicated CD19-targeted therapy-resistant human leukemia and lymphoma...
Post
Unravelling the mystery of how one gene contributes to Parkinson’s, Crohn’s and leprosy
Research on LRRK2 gene in mice could lead to new treatments, prevention THE OTTAWA HOSPITAL Researchers have struggled for years to understand how mutations in one gene, called LRRK2, can increase the risk of three very different diseases: Parkinson’s (a brain disease), Crohn’s (a gut disease) and leprosy (a peripheral nervous system disease). Now, a Canadian team has found that inflammation is the likely culprit....
Post
Technique can image individual proteins within synapses
Rapid imaging method could help reveal how conditions such as autism affect brain cells MASSACHUSETTS INSTITUTE OF TECHNOLOGY CAMBRIDGE, MA — Our brains contain millions of synapses — the connections that transmit messages from neuron to neuron. Within these synapses are hundreds of different proteins, and dysfunction of these proteins can lead to conditions such...
Post
New genes identified in hearing loss, providing treatment hope
KING’S COLLEGE LONDON A new study published today in The American Journal of Human Genetics has identified 44 genes linked to age-related hearing loss giving a much clearer understanding of how the condition develops and potential treatments. In the study, researchers from King’s College London and UCL analysed the genetic data from over 250,000 participants...
Post
Investigational drug with immunotherapy may provide new therapeutic opportunity for patients previously treated for kidney and lung cancer
Pegilodecakin with pembrolizumab and nivolumab shown to be safe in Phase 1B study UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER HOUSTON — Pegilodecakin, a first-in-class drug currently in clinical trials, has shown positive safety results and may offer a potential new treatment avenue for patients with non-small cell lung cancer (NSCLC) and kidney cancer....